Learn more about our flagship Areas
The precision medicine flagship initiative offers Personalized Medicine services to all citizens through the Public Healthcare System. smartHEALTH partners are engaged in the implementation of the Precision Medicine Unit of Crete, while they also participate in all 4 of the National Networks in Precision Medicine (Oncology, Cardiology, Neurodegenerative diseases and COVID19).
smartHEALTH partners have extensive experience in radiomics and radiogenomics methods and applications for oncology focusing on hybrid imaging systems such as MRI/PET, translational bioinformatics, deep learning in computational medical imaging, in silico cancer modelling, AI and mechanistic modelling for clinical decision making in oncology, novel pharmacokinetic models for better addressing the underlying cancer biological processes, image analysis technologies for cancer assessment and tumor microenvironment identification. There are long term collaborations in place with national and European clinical organizations for assisting the clinical evaluation and translation of these tools and biomarkers to the clinical setting.
Public Sector Digital Transformation
Extensive work has been done on identifying European and international policies and best practices, EU directives and work programmes in order to enhance the modernization of the public sector and the development and implementation of innovative services. In this way the prevention, prediction, diagnosis, treatment and monitoring for all citizens in emergency, primary, secondary and tertiary care, civil protection, and social services across the customer journey will be better supported. Emphasis is given to interoperability, standards, regulations, privacy and safety through the exploitation of outcomes of several innovation projects and available expertise already in place at smartHEALTH.
Infrastructure - HMIU
A molecular imaging facility which hosts a pre-clinical micro-PET/MRI scanner is available at smartHEALTH. The MR component produces a high intensity MR field (4.7 Tesla), while the system enables simultaneous PET and MRI acquisition, allowing temporal synchronization of the data that are acquired from the two modalities providing unique molecular imaging research capabilities. This infrastructure lies on top of the recent technological innovation in the field of pre-clinical molecular imaging instrumentation and constitutes a unique research facility in south – east Europe, holding promise for both short- and long-term benefits in the development of novel therapeutic strategies for various diseases in the fields of oncology, cardiology, neurology, autoimmune diseases, musculoskeletal disorders, rare diseases and syndromes.